ARTICLE | Company News
Oxford GlycoSciences gets fast track for Gaucher
June 20, 2000 7:00 AM UTC
Oxford GlycoSciences (LSE:OGS) received FDA Fast Track designation for its OGT 918 oral glucosyltransferase inhibitor to treat Gaucher disease. The product is in Phase I/II development. ...